AGEN - Agenus Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Lexington,
United States
Type: Equity
AGEN price evolution
AGEN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $93.72 | $52.86 | $76.11 | |
| Short term investments | ||||
| Net receivables | $0.21 | $0.72 | $0.48 | $25.84 |
| Inventory | ||||
| Total current assets | $50.15 | $100 | $60.35 | $112.42 |
| Long term investments | ||||
| Property, plant & equipment | $153.08 | $156.53 | $159.67 | $163.03 |
| Goodwill & intangible assets | $28.88 | $28.93 | $29.13 | |
| Total noncurrent assets | $192.41 | $196.21 | $201.5 | |
| Total investments | ||||
| Total assets | $238.48 | $292.42 | $256.56 | $313.91 |
| Current liabilities | ||||
| Accounts payable | $45.9 | $50.84 | $50.69 | $61.45 |
| Deferred revenue | $1.15 | $1.16 | $1.16 | |
| Short long term debt | $15.72 | $16.39 | $2.73 | |
| Total current liabilities | $270.64 | $270.67 | $256 | $255.9 |
| Long term debt | $55.79 | $61.76 | $75.28 | |
| Total noncurrent liabilities | $242.59 | $190.88 | $206.4 | |
| Total debt | $71.51 | $78.14 | $78.01 | |
| Total liabilities | $530.82 | $513.25 | $446.88 | $462.3 |
| Shareholders' equity | ||||
| Retained earnings | -$2137.02 | -$2070.64 | -$2017.55 | -$1955.67 |
| Other shareholder equity | -$1.35 | -$1 | -$1.07 | -$0.95 |
| Total shareholder equity | -$241.31 | -$201.43 | -$160.33 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $76.11 | $178.67 | $291.93 | $99.87 |
| Short term investments | $14.68 | $14.99 | ||
| Net receivables | $25.84 | $2.74 | $1.52 | $1.16 |
| Inventory | ||||
| Total current assets | $112.42 | $213.12 | $331.97 | $113.78 |
| Long term investments | ||||
| Property, plant & equipment | $163.03 | $164.29 | $91.08 | $60.27 |
| Goodwill & intangible assets | $29.13 | $31.7 | $33.36 | $36.34 |
| Total noncurrent assets | $201.5 | $200.43 | $133.98 | $100.73 |
| Total investments | $14.68 | $14.99 | ||
| Total assets | $313.91 | $413.56 | $465.96 | $214.51 |
| Current liabilities | ||||
| Accounts payable | $61.45 | $40.94 | $30.49 | $17.02 |
| Deferred revenue | $1.16 | $13.41 | $23.63 | $45.47 |
| Short long term debt | $2.73 | $2.52 | $3.35 | $2.78 |
| Total current liabilities | $255.9 | $188.95 | $156.94 | $129.88 |
| Long term debt | $75.28 | $24.85 | $54.93 | $52.94 |
| Total noncurrent liabilities | $206.4 | $279.51 | $261.11 | $296.13 |
| Total debt | $78.01 | $78.43 | $58.29 | $55.73 |
| Total liabilities | $462.3 | $474.83 | $418.05 | $426.01 |
| Shareholders' equity | ||||
| Retained earnings | -$1955.67 | -$1709.91 | -$1489.83 | -$1465.91 |
| Other shareholder equity | -$0.95 | $0.92 | $1.49 | $2.77 |
| Total shareholder equity | -$160.33 | -$61.28 | $34.44 | -$203.67 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $25.11 | $23.51 | $28 | $83.8 |
| Cost of revenue | $0.12 | $0.11 | $0.26 | |
| Gross Profit | $24.97 | $23.39 | $27.9 | $83.54 |
| Operating activities | ||||
| Research & development | $36.77 | $43.92 | $66.72 | |
| Selling, general & administrative | $16.82 | $16.86 | $21.18 | |
| Total operating expenses | $58.33 | $53.59 | $60.78 | $87.9 |
| Operating income | -$30.19 | -$32.88 | -$4.36 | |
| Income from continuing operations | ||||
| EBIT | -$21.34 | -$32.42 | -$2.11 | |
| Income tax expense | ||||
| Interest expense | -$33.87 | $31.75 | $29.47 | $44.18 |
| Net income | ||||
| Net income | -$66.44 | -$53.08 | -$61.89 | -$46.29 |
| Income (for common shares) | -$53.13 | -$61.94 | -$46.34 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $156.31 | $98.02 | $295.67 | $88.17 |
| Cost of revenue | $3.11 | $10.57 | $3.47 | $2.35 |
| Gross Profit | $153.2 | $87.46 | $292.19 | $85.82 |
| Operating activities | ||||
| Research & development | $234.57 | $186.69 | $178.61 | $142.62 |
| Selling, general & administrative | $78.74 | $81.01 | $76.36 | $59.22 |
| Total operating expenses | $313.31 | $267.7 | $254.97 | $201.84 |
| Operating income | -$160.1 | -$180.24 | $37.23 | -$116.01 |
| Income from continuing operations | ||||
| EBIT | -$147.84 | -$158.21 | $41.79 | -$119.84 |
| Income tax expense | ||||
| Interest expense | $97.92 | $61.86 | $65.72 | $61.08 |
| Net income | ||||
| Net income | -$245.76 | -$220.07 | -$23.93 | -$180.91 |
| Income (for common shares) | -$245.97 | -$220.29 | -$24.14 | -$181.12 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$53.08 | -$61.89 | -$46.29 | |
| Operating activities | ||||
| Depreciation | $3.36 | $3.37 | $5.2 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $4.03 | $4.15 | $5.46 | |
| Total cash flows from operations | -$38.18 | -$38.19 | -$40.4 | |
| Investing activities | ||||
| Capital expenditures | -$0.46 | -$0.04 | $2.79 | |
| Investments | $0.22 | $0.26 | $0.03 | |
| Total cash flows from investing | $0.05 | -$0.24 | $0.23 | $2.82 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.02 | $17.34 | $9.98 | |
| Net borrowings | -$2.59 | -$2.51 | -$2.62 | |
| Total cash flows from financing | $98.47 | $79.08 | $14.83 | $7.32 |
| Effect of exchange rate | -$0.22 | $0.17 | -$0.12 | $0.07 |
| Change in cash and equivalents | -$31.36 | $40.83 | -$23.25 | -$30.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$245.76 | -$220.07 | -$23.93 | -$180.91 |
| Operating activities | ||||
| Depreciation | $13.59 | $6.95 | $6.79 | $7.18 |
| Business acquisitions & disposals | -$2.92 | -$0.97 | ||
| Stock-based compensation | $22.87 | $18.34 | $19.58 | $10.42 |
| Total cash flows from operations | -$224.2 | -$175.37 | $10.14 | -$139.1 |
| Investing activities | ||||
| Capital expenditures | -$6.59 | -$31.06 | -$28.16 | -$3.47 |
| Investments | $9.99 | $0.37 | -$14.99 | |
| Total cash flows from investing | $3.4 | -$33.61 | -$43.15 | -$4.44 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $129.4 | $96.32 | $205.13 | $180.89 |
| Net borrowings | -$8.93 | -$0.49 | -$1.32 | $2.96 |
| Total cash flows from financing | $119.87 | $95.83 | $225.26 | $183.85 |
| Effect of exchange rate | -$0.63 | -$0.1 | -$0.16 | $0.38 |
| Change in cash and equivalents | -$101.56 | -$113.26 | $192.09 | $40.7 |
News
Fundamentals
| Market cap | $76.98M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 21.69M |
| Revenue | $160.43M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$227.70M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.34 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.48 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$10.50 |
|---|---|
| ROA | -82.70% |
| ROE | N/A |
| Debt/Equity | -2.88 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.19 |
| Quick ratio | N/A |